体外二氧化碳清除避免慢性阻塞性肺疾病急性加重期有创通气:VENT-AVOID 随机临床试验
VENT-AVOID试验为随机临床试验,在美国41家机构(2018-2022年)纳入113例COPD急性加重、NIV失败或IMV脱机失败的患者,随机分为标准治疗联合静脉-静脉ECCO2R组(NIV层n=26,IMV层n=32)或单纯标准治疗组(NIV层n=22,IMV层n=33)。因入组缓慢提前终止,实际纳入113例,计划样本量为180例。按分层控制后,两组中位VFD-5无显著差异(P=0.36):NIV层两组中位VFD-5均为5天(中位偏移0.0,95%CI 0.0-0.0);IMV层标准治疗组0.25天 vs ECCO2R组2天(中位偏移0.00,95%CI 0.00-1.25)。NIV层ECCO2R组全因院内死亡率显著更高(22% vs 0%,P=0.02),IMV层两组无差异(17% vs 15%,P=0.73)。
要点
- COPD急性加重NIV失败或IMV脱机失败患者中,ECCO2R组与标准治疗组中位VFD-5无显著差异(P=0.36)。
- NIV层两组中位VFD-5均为5天(中位偏移0.0,95%CI 0.0-0.0)。
- IMV层标准治疗组中位VFD-5为0.25天 vs ECCO2R组2天(中位偏移0.00,95%CI 0.00-1.25)。
- NIV层ECCO2R组全因院内死亡率显著更高(22% vs 0%,P=0.02)。
- IMV层全因院内死亡率两组无差异(17% vs 15%,P=0.73)。
适用人群与场景
- COPD急性加重且NIV失败或IMV脱机失败的成人患者
- 美国41家机构,2018-2022年
- NIV层:ECCO2R组n=26,标准治疗组n=22
- IMV层:ECCO2R组n=32,标准治疗组n=33
处置流程与药物剂量
- 标准治疗联合静脉-静脉ECCO2R,或单纯标准治疗
研究设计与关键结果
- 随机临床试验,美国41家机构(2018-2022年),纳入113例(计划样本量180例),因入组缓慢提前终止
- 按分层控制后两组中位VFD-5无显著差异(P=0.36)
- NIV层两组中位VFD-5均为5天(中位偏移0.0,95%CI 0.0-0.0)
- IMV层标准治疗组中位VFD-5为0.25天 vs ECCO2R组2天(中位偏移0.00,95%CI 0.00-1.25)
- NIV层全因院内死亡率ECCO2R组22% vs 标准治疗组0%(P=0.02)
- IMV层全因院内死亡率ECCO2R组17% vs 标准治疗组15%(P=0.73)
证据类型、等级与局限
- 随机临床试验
- 因入组缓慢提前终止,实际纳入113例(计划样本量180例)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: It is unclear whether extracorporeal CO2 removal (ECCO2R) can reduce the rate of intubation or the total time on invasive mechanical ventilation (IMV) in adults experiencing an exacerbation of chronic obstructive pulmonary disease (COPD). Objectives: To determine whether ECCO2R increases the number of ventilator-free days within the first 5 days postrandomization (VFD-5) in exacerbation of COPD in patients who are either failing noninvasive ventilation (NIV) or who are failing to wean from IMV. Methods: This randomized clinical trial was conducted in 41 U.S. institutions (2018-2022) (ClinicalTrials.gov ID: NCT03255057). Subjects were randomized to receive either standard care with venovenous ECCO2R (NIV stratum: n = 26; IMV stratum: n = 32) or standard care alone (NIV stratum: n = 22; IMV stratum: n = 33). Measurements and Main Results: The trial was stopped early because of slow enrollment and enrolled 113 subjects of the planned sample size of 180. There was no significant difference in the median VFD-5 between the arms controlled by strata (P = 0.36). In the NIV stratum, the median VFD-5 for both arms was 5 days (median shift = 0.0; 95% confidence interval [CI]: 0.0-0.0). In the IMV stratum, the median VFD-5 in the standard care and ECCO2R arms were 0.25 and 2 days, respectively; median shift = 0.00 (95% confidence interval: 0.00-1.25). In the NIV stratum, all-cause in-hospital mortality was significantly higher in the ECCO2R arm (22% vs. 0%, P = 0.02) with no difference in the IMV stratum (17% vs. 15%, P = 0.73). Conclusions: In subjects with exacerbation of COPD, the use of ECCO2R compared with standard care did not improve VFD-5. Clinical trial registered with www.clinicaltrials.gov (NCT03255057).
参考来源
- Duggal A, Conrad SA, Barrett NA, et al. Extracorporeal Carbon Dioxide Removal to Avoid Invasive Ventilation During Exacerbations of Chronic Obstructive Pulmonary Disease: VENT-AVOID Trial - A Randomized Clinical Trial. Am J Respir Crit Care Med. 2024. PMID: 38261630. doi:10.1164/rccm.202311-2060OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。